InsidersTradesSigma
Phaxiam Therapeutics Stock: price and management transactions · France · AMF
Follow the Phaxiam Therapeutics stock price and the full directors' dealings record of the company, a listed issuer based in France. Shares are quoted on FR FR, under the supervision of AMF. Operating in the Healthcare & Pharma sector, Phaxiam Therapeutics has published 7 reports. Market capitalisation: €1k. The latest transaction was filed on 15 October 2024 (Acquisition). Among the most active insiders: GO CAPITAL SAS. The full history is openly available.
7
Insider Decl.
0
Thresholds
€22,052
1 ops.
Buy Volume
·
0 ops.
Sell Volume
30Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 15 October 2024
Declarations7 total
22,052 shares@ €1.00100.0% of flowActionEuronext Paris2024DD1000137
Ideal exit: 5 Jul 2025 (T+270)
22,052 shares0ActionEuronext Paris2024DD1000544
Ideal exit: 5 Jul 2025 (T+270)
71,839 shares@ €0.61100.0% of flowActionHors plateforme de négociation2023DD918283
54,862 shares@ €0.61100.0% of flowActionHors plateforme de négociation2023DD917744
3,697,533 shares@ €0.6163.6% of flowActionHors plateforme de négociation2023DD917607
1,058,535 shares@ €0.6118.2% of flowActionHors plateforme de négociation2023DD900707
1,058,535 shares@ €0.6118.2% of flowActionHors plateforme de négociation2023DD900711
7 of 7 declarations
About Phaxiam Therapeutics
PHAXIAM THERAPEUTICS is a French biopharmaceutical company focused on the development of innovative treatments for severe and drug-resistant bacterial infections. Its scientific platform is built around phage therapy, a therapeutic approach that uses bacteriophages — naturally occurring viruses that kill specific bacteria — to address one of the most pressing public health challenges: antibiotic resistance. PHAXIAM has structured its portfolio around phages targeting three especially problematic hospital pathogens: Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, which its public communications indicate account for more than two-thirds of resistant hospital-acquired infections. The company’s recent history reflects a strategic repositioning from Erytech into a pure-play phage therapy company. Headquartered in Lyon, France, PHAXIAM also maintained a presence in Cambridge, Massachusetts, giving it a transatlantic footprint that supports clinical development, scientific partnerships, and access to the broader biotech ecosystem. Throughout 2024, the company continued to advance its clinical and industrial roadmap while regularly updating the market on operational and financial progress. Clinically, PHAXIAM has built much of its reputation around bone and joint infections, especially prosthetic joint infections (PJI), an area where it described itself as the most advanced phage-therapy player in Europe. The company has reported encouraging data from its clinical programs, including PhagoDAIR and the GLORIA Phase II program, which are intended to demonstrate the safety and efficacy of phages as an adjunct to standard-of-care treatment. In January 2025, PHAXIAM also announced a strategic collaboration with Technophage to develop individualized GMP phage therapies (IPT), broadening the industrial and therapeutic potential of its platform. PHAXIAM is listed on Euronext Paris under ISIN FR001400K4B1 and ticker PHXM. The company raised financing in 2024 to support development efforts, and in June 2025 it announced the suspension of trading ahead of a delisting process. Based on the latest public information reviewed, PHAXIAM remains a specialized, high-innovation biotechnology company positioned in the fight against antimicrobial resistance.
